SUBSCRIBE
SUBSCRIBE

Indications

PRESS RELEASES
Press Releases
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
March 3, 2026
 · 
7 min read
Press Releases
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
March 2, 2026
 · 
4 min read
Press Releases
Health Canada Approves Ozempic® (semaglutide injection) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) in Adults with Type 2 Diabetes
March 2, 2026
 · 
7 min read
Press Releases
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
March 2, 2026
 · 
9 min read
Press Releases
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
March 2, 2026
 · 
4 min read
Press Releases
FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
March 2, 2026
 · 
13 min read
Press Releases
Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
February 26, 2026
 · 
13 min read
Press Releases
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
February 26, 2026
 · 
12 min read
Press Releases
Olympus Announces Pediatric Use Indication for Two Single-Use Bronchoscopes
February 24, 2026
 · 
3 min read
Press Releases
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
February 24, 2026
 · 
19 min read
Press Releases
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
February 24, 2026
 · 
28 min read
Press Releases
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 24, 2026
 · 
5 min read
Press Releases
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
February 23, 2026
 · 
15 min read
Press Releases
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
February 23, 2026
 · 
6 min read
Press Releases
New indication in pediatric patients, including term neonates for Guerbet’s half-dose GBCA, Elucirem™ (Gadopiclenol) Injection
February 22, 2026
 · 
8 min read
Press Releases
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
February 19, 2026
 · 
8 min read
Press Releases
Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma
February 19, 2026
 · 
4 min read
Press Releases
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
 · 
10 min read
Press Releases
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
February 18, 2026
 · 
7 min read
Press Releases
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
February 18, 2026
 · 
8 min read
Load More